2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy

Canadian Journal of Cardiology

Volumn 34, Issue 3, 2018, Pages 214-233

  Mehta, Shamir R ^a   Bainey, Kevin R ^b   Cantor, Warren J ^c   Lordkipanidzé, Marie ^d   Marquis Gravel, Guillaume ^d   Robinson, Simon D ^e   Sibbald, Matthew ^a   So, Derek Y ^f   Wong, Graham C ^g   Abunassar, Joseph G ^f   Ackman, Margaret L ^b   Bell, Alan D ^h   Cartier, Raymond ^d   Douketis, James D ⁱ   Lawler, Patrick R ^j   McMurtry, Michael S ^b   Udell, Jacob A ^j   van Diepen, Sean ^b   Verma, Subodh ^k   Mancini, G B John ^g   Cairns, John A ^g   Tanguay, Jean François ^d   Armstrong, Paul W ^l   Bagai, Akshay ^l   Bucci, Claudia ^l   Déry, Jean Pierre ^l   Diodati, Jean ^l   Dupuis, Jocelyn ^l   Fitchett, David ^l   Love, Michael P ^l   Welsh, Robert ^l   more..

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^c SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^g VANCOUVER GENERAL HOSPITAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j WOMEN S COLLEGE HOSPITAL   (Canada)

^k ST MICHAEL'S HOSPITAL   (Canada)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CANADIAN; CARDIOLOGY; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG USE; DUAL ANTIPLATELET THERAPY; ELECTIVE SURGERY; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGERY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CANADA; CORONARY ARTERY DISEASE; FEMALE; FORECASTING; MALE; STANDARDS; TREATMENT OUTCOME; TRENDS;

ACUTE CORONARY SYNDROME; CANADA; CARDIOLOGY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; FORECASTING; HUMANS; MALE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 85042672578     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2017.12.012     Document Type: Article

References (130)

1. Bell, A.D., Roussin, A., Cartier, R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 27:suppl A (2011), S1–S59.
2. Tanguay, J.F., Bell, A.D., Ackman, M.L., et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 29 (2013), 1334–1345.
3. Guyatt, G.H., Oxman, A.D., Vist, G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
4. Grade Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE), 2016. Available at: www.gradeworkinggroup.org. Accessed January 26, 2017.
5. Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
6. Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
7. Schulz-Schupke, S., Byrne, R.A., Ten Berg, J.M., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 36 (2015), 1252–1263.
8. Gilard, M., Barragan, P., Noryani, A.A., et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 65 (2015), 777–786.
9. Colombo, A., Chieffo, A., Frasheri, A., et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
10. Feres, F., Costa, R.A., Abizaid, A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
11. Kim, B.K., Hong, M.K., Shin, D.H., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
12. Gwon, H.C., Hahn, J.Y., Park, K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
13. Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
14. Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
15. Giustino, G., Chieffo, A., Palmerini, T., et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 68 (2016), 1851–1864.
16. Costa, F., Adamo, M., Ariotti, S., et al. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. Eurointervention 11 (2016), e1222–e1230.
17. Lee, S.Y., Hong, M.K., Shin, D.H., et al. Association between duration of dual antiplatelet therapy and angiographic multivessel disease on outcomes in patients treated with newer-generation drug-eluting stents. Circ Cardiovasc Interv, 9, 2016, e004256.
18. Bundhun, P.K., Yanamala, C.M., Huang, F., Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord, 16, 2016, 161.
19. Yeh, R.W., Secemsky, E.A., Kereiakes, D.J., et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
20. Baber, U., Dangas, G., Cohen, D.J., et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J 182 (2016), 125–134.
21. ClinicalTrials.gov. GLOBAL LEADERS. A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01813435 Accessed January 17, 2017.
22. Costa, F., van Klaveren, D., James, S., et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389 (2017), 1025–1034.
23. Pasea, L., Chung, S.C., Pujades-Rodriguez, M., et al. Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J 38 (2017), 1048–1055.
24. Baber, U., Mehran, R., Giustino, G., et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67 (2016), 2224–2234.
25. Dehghani, P., Lavoie, A., Lavi, S., et al. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. Am Heart J 192 (2017), 105–112.
26. Han, Y., Xu, B., Xu, K., et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv, 9, 2016, e003145.
27. Hong, S.J., Shin, D.H., Kim, J.S., et al. 6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 9 (2016), 1438–1446.
28. Abo-Salem, E., Alsidawi, S., Jamali, H., Effat, M., Helmy, T., Optimal duration of dual antiplatelet therapy after drug-eluting stents: meta-analysis of randomized trials. Cardiovasc Ther 33 (2015), 253–263.
29. Liou, K., Nagaraja, V., Jepson, N., Ooi, S.Y., Optimal duration of dual antiplatelet therapy following drug-eluting stents implantation: a meta-analysis of 7 randomised controlled trials. Int J Cardiol 201 (2015), 578–580.
30. Navarese, E.P., Andreotti, F., Schulze, V., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350, 2015, h1618.
31. Tsoi, M.F., Cheung, C.L., Cheung, T.T., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of large randomised controlled trials. Sci Rep, 5, 2015, 13204.
32. Villablanca, P.A., Massera, D., Mathew, V., et al. Outcomes of
33. Wassef, A.W., Khafaji, H., Syed, I., et al. Short duration vs standard duration of dual-antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents - a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. J Invasive Cardiol 28 (2016), E203–E210.
34. Yang, J., Fan, Z.X., Yang, C.J., Wang, H.B., A meta-analysis of randomized clinical trials comparing shorter (less or equal than 6 months) and longer (more or equal than 12 months) dual anti-platelet therapy following drug-eluting coronary stents. Iran Red Crescent Med J, 17, 2015, e26904.
35. Zhang, X.L., Zhu, Q.Q., Zhu, L., et al. Optimize the duration of DAPT following DES implantation: an updated system review and meta-analysis of 10 randomized trials. Clin Trials Regul Sci Cardiol 6 (2015), 1–11.
36. Ziada, K.M., Abdel-Latif, A.K., Charnigo, R., Moliterno, D.J., Safety of an abbreviated duration of dual antiplatelet therapy (
37. Valgimigli, M., Ariotti, S., Costa, F., Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?. Eur Heart J 36 (2015), 1219–1222.
38. Sheyin, O., Perez, X., Pierre-Louis, B., Kurian, D., The optimal duration of dual antiplatelet therapy in patients receiving percutaneous coronary intervention with drug-eluting stents. Cardiol J 23 (2016), 307–316.
39. Sharma, A., Sharma, S.K., Garg, A., et al. Duration of dual antiplatelet therapy following drug-eluting stent implantation in diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. JACC Cardiovasc Interv, 1, 2016, S6.
40. Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385 (2015), 2371–2382.
41. Fei, Y., Tsoi, M.F., Cheung, T.T., Cheung, B.M., Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of randomized controlled trials. Int J Cardiol 220 (2016), 895–900.
42. Eikelboom, J.W., Connolly, S.J., Bosch, J., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377 (2017), 1319–1330.
43. Devereaux, P.J., Mrkobrada, M., Sessler, D.I., et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 370 (2014), 1494–1503.
44. Holcomb, C.N., Graham, L.A., Richman, J.S., et al. The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. J Am Coll Cardiol 64 (2014), 2730–2739.
45. Egholm, G., Kristensen, S.D., Thim, T., et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 68 (2016), 2622–2632.
46. Rossini, R., Angiolillo, D.J., Musumeci, G., et al. Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: results of the surgery after stenting registry. Catheter Cardiovasc Interv 89 (2017), E13–E25.
47. Myles, P.S., Smith, J.A., Painter, T., Aspirin before coronary artery surgery. N Engl J Med 375 (2016), 91–92.
48. Mangano, D.T., Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 347 (2002), 1309–1317.
49. Dacey, L.J., Munoz, J.J., Johnson, E.R., et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 70 (2000), 1986–1990.
50. Bybee, K.A., Powell, B.D., Valeti, U., et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 112 (2005), I286–I292.
51. Hansson, E.C., Jideus, L., Aberg, B., et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 37 (2016), 189–197.
52. Held, C., Asenblad, N., Bassand, J.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57 (2011), 672–684.
53. Biancari, F., Airaksinen, K.E., Lip, G.Y., Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg 143 (2012), 665–675.e4.
54. Gherli, R., Mariscalco, G., Dalen, M., et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 1 (2016), 921–928.
55. Mehta, R.H., Roe, M.T., Mulgund, J., et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 48 (2006), 281–286.
56. Fox, K.A., Mehta, S.R., Peters, R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 110 (2004), 1202–1208.
57. Smith, P.K., Goodnough, L.T., Levy, J.H., et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 60 (2012), 388–396.
58. Alexopoulos, D., Xanthopoulou, I., Deftereos, S., et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 167 (2014), 68–76.e2.
59. Clemmensen, P., Grieco, N., Ince, H., et al. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel–the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care 4 (2015), 220–229.
60. Bagai, A., Peterson, E.D., Honeycutt, E., et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care 4 (2015), 499–508.
61. De Luca, L., Leonardi, S., Cavallini, C., et al. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT Study. Eur Heart J Acute Cardiovasc Care 4 (2015), 441–452.
62. Bagai, A., Wang, Y., Wang, T.Y., et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 7 (2014), 585–593.
63. De Luca, G., Verdoia, M., Schaffer, A., et al. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. J Thromb Thrombolysis 38 (2014), 388–394.
64. Loh, J.P., Pendyala, L.K., Kitabata, H., et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 111 (2013), 841–845.
65. Almendro-Delia, M., Blanco Ponce, E., Gomez-Dominguez, R., et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the ‘real world’. J Thromb Thrombolysis 39 (2015), 499–507.
66. Pourdjabbar, A., Hibbert, B., Chong, A.Y., et al. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. Thromb Haemost 117 (2017), 303–310.
67. Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
68. Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
69. Caiazzo, G., De Rosa, S., Torella, D., et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ Cardiovasc Interv 7 (2014), 104–112.
70. Lhermusier, T., Voisin, S., Murat, G., et al. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol 174 (2014), 874–876.
71. Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
72. Angiolillo, D.J., Saucedo, J.F., Deraad, R., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56 (2010), 1017–1023.
73. Payne, C.D., Li, Y.G., Brandt, J.T., et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 19 (2008), 275–281.
74. Diodati, J.G., Saucedo, J.F., French, J.K., et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv 6 (2013), 567–574.
75. Lhermusier, T., Lipinski, M.J., Drenning, D., et al. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol 27 (2014), 365–372.
76. Raber, L., Klingenberg, R., Heg, D., et al. Safety of prasugrel loading doses in patients pre-loaded with clopidogrel in the setting of primary percutaneous coronary intervention: results of a nonrandomized observational study. JACC Cardiovasc Interv 8 (2015), 1064–1074.
77. Franchi, F., Faz, G.T., Rollini, F., et al. Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study. JACC Cardiovasc Interv 9 (2016), 1089–1098.
78. Angiolillo, D.J., Curzen, N., Gurbel, P., et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J Am Coll Cardiol 63 (2014), 1500–1509.
79. Cuisset, T., Deharo, P., Quilici, J., et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 38 (2017), 3070–3078.
80. Gurbel, P.A., Bliden, K.P., Butler, K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (2010), 1188–1199.
81. Sibbing, D., Aradi, D., Jacobshagen, C., et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390 (2017), 1747–1757.
82. Kralev, S., Schneider, K., Lang, S., Suselbeck, T., Borggrefe, M., Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One, 6, 2011, e24964.
83. Schmitt, J., Duray, G., Gersh, B.J., Hohnloser, S.H., Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30 (2009), 1038–1045.
84. Mehta, S.R., Yusuf, S., Clopidogrel in Unstable angina to prevent Recurrent Events Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21 (2000), 2033–2041.
85. Chen, Z.M., Jiang, L.X., Chen, Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005), 1607–1621.
86. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
87. ACTIVE Writing Group of the ACTIVE Investigators, Connolly, S., Pogue, J., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006), 1903–1912.
88. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
89. Verma, A., Cairns, J.A., Mitchell, L.B., et al. 2014 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 30 (2014), 1114–1130.
90. Macle, L., Cairns, J., Leblanc, K., et al. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 32 (2016), 1170–1185.
91. Hylek, E.M., Held, C., Alexander, J.H., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63 (2014), 2141–2147.
92. Dans, A.L., Connolly, S.J., Wallentin, L., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127 (2013), 634–640.
93. Xu, H., Ruff, C.T., Giugliano, R.P., et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial. J Am Heart Assoc, 5, 2016, e002587.
94. Goodman, S.G., Wojdyla, D.M., Piccini, J.P., et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 63 (2014), 891–900.
95. Hansen, M.L., Sorensen, R., Clausen, M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
96. D'Ascenzo, F., Taha, S., Moretti, C., et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol 115 (2015), 1185–1193.
97. Dewilde, W.J., Oirbans, T., Verheugt, F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
98. Fiedler, K.A., Maeng, M., Mehilli, J., et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 65 (2015), 1619–1629.
99. Gibson, C.M., Mehran, R., Bode, C., et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375 (2016), 2423–2434.
100. Gibson, C.M., Pinto, D.S., Chi, G., et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation 135 (2017), 323–333.
101. Cannon, C.P., Bhatt, D.L., Oldgren, J., et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377 (2017), 1513–1524.
102. Bourguignon, T., Bergoend, E., Mirza, A., et al. Risk factors for valve-related complications after mechanical heart valve replacement in 505 patients with long-term follow up. J Heart Valve Dis 20 (2011), 673–680.
103. Edmunds, L.H. Jr., Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 44 (1987), 430–445.
104. Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
105. Lin, S.S., Tiong, I.Y., Asher, C.R., et al. Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiography. Am J Cardiol 86 (2000), 1097–1101.
106. Laplace, G., Lafitte, S., Labeque, J.N., et al. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll Cardiol 43 (2004), 1283–1290.
107. Sundt, T.M., Zehr, K.J., Dearani, J.A., et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. J Thorac Cardiovasc Surg 129 (2005), 1024–1031.
108. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 (2017), 252–289.
109. Gilard, M., Blanchard, D., Helft, G., et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 104 (2009), 338–342.
110. Karjalainen, P.P., Porela, P., Ylitalo, A., et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28 (2007), 726–732.
111. Rubboli, A., Colletta, M., Valencia, J., et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 22 (2009), 390–397.
112. Rubboli, A., Sciahbasi, A., Briguori, C., et al. In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. J Invasive Cardiol 25 (2013), 170–176.
113. Sambola, A., Ferreira-Gonzalez, I., Angel, J., et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 95 (2009), 1483–1488.
114. Sarafoff, N., Martischnig, A., Wealer, J., et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 61 (2013), 2060–2066.
115. Sarafoff, N., Ndrepepa, G., Mehilli, J., et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 264 (2008), 472–480.
116. Uchida, Y., Mori, F., Ogawa, H., Takagi, A., Hagiwara, N., Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol 55 (2010), 362–369.
117. Adams, D.H., Popma, J.J., Reardon, M.J., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
118. Leon, M.B., Smith, C.R., Mack, M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 (2010), 1597–1607.
119. Leon, M.B., Smith, C.R., Mack, M.J., et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 (2016), 1609–1620.
120. Kearon, C., Natural history of venous thromboembolism. Circulation 107 (2003), I22–30.
121. Hull, R., Delmore, T., Genton, E., et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301 (1979), 855–858.
122. Nielsen, H.K., Husted, S.E., Krusell, L.R., et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb Res 73 (1994), 215–226.
123. Kearon, C., Akl, E.A., Ornelas, J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149 (2016), 315–352.
124. Delewi, R., Zijlstra, F., Piek, J.J., Left ventricular thrombus formation after acute myocardial infarction. Heart 98 (2012), 1743–1749.
125. Solheim, S., Seljeflot, I., Lunde, K., et al. Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy. Am J Cardiol 106 (2010), 1197–1200.
126. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 (2013), e362–e425.
127. Nikolsky, E., Mehran, R., Dangas, G.D., et al. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol 109 (2012), 831–838.
128. Udell, J.A., Wang, J.T., Gladstone, D.J., Tu, J.V., Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One, 5, 2010, e12150.
129. Le May, M.R., Acharya, S., Wells, G.A., et al. Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 8 (2015), 155–162.
130. Shavadia, J.S., Youngson, E., Bainey, K.R., Bakal, J., Welsh, R.C., Outcomes and prognostic impact of prophylactic oral anticoagulation in anterior ST-segment elevation myocardial infarction patients with left ventricular dysfunction. J Am Heart Assoc, 6, 2017, e006054.